Rejuvenated Investor Confidence Fuels Benitec Biopharma’s Successful $40 Million Private Placement Financing
HAYWARD, Calif. April 18, 2024 – Benitec Biopharma Inc. (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy, proudly announced today the successful completion of an oversubscribed private investment in public equity (PIPE) financing, securing an impressive $40.0 million. This financing round exemplifies the increased investor confidence in Benitec’s mission to develop revolutionary genetic medicines using their groundbreaking Silence and Replace DNA-directed RNA interference (ddRNAi) platform.
Leading this oversubscribed financing was Suvretta Capital Management, LLC, alongside a range of institutional accredited investors including Adage Capital Partners L.P. Nantahala Capital, several healthcare-focused funds, and a prominent mutual fund. The offering involved the sale of 5,749,152 shares of common stock at a price of $4.80 per share and pre-funded warrants granting the option to purchase an aggregate of 2,584,239 shares of common stock at a price of $4.7999 per pre-funded warrant.
Benitec’s commendable ability to secure this significant financing is a testament to the company’s position as a frontrunner in the biotech industry. The $40.0 million raised in gross proceeds will provide Benitec with the means to propel its cutting-edge gene therapy research and development initiatives forward while expanding its pipeline of innovative treatment solutions.
Despite the company’s recent successes, it is noteworthy to mention that Benitec Biopharma Inc shares experienced a slight decline of 7.84% in April 2024. However, this should not overshadow the impressive developments and the affirmation of investors’ belief in Benitec’s potential, as demonstrated by the resounding success of the PIPE financing.
With the financial resources at its disposal, Benitec Biopharma Inc is poised to continue forging ahead, aiming to accelerate clinical trials, expand its talented team of researchers, and bring its transformative genetic medicines to market faster. This landmark financing round signifies a new chapter in Benitec’s journey, marking it as one of the industry leaders driving advancements in gene therapy-based treatments.
In conclusion, Benitec Biopharma Inc’s $40.0 million private placement financing marks a significant milestone in the company’s mission to revolutionize genetic medicine. The unwavering support from both new and existing investors underscores the industry’s recognition of Benitec’s innovative approach and immense potential. With this substantial funding, Benitec Biopharma Inc is now poised to accelerate its research and development efforts and make substantial progress in bringing novel genetic therapies to patients in need.
Comments